Çağatay Taşkıran
A5090765165- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Cancer Immunotherapy and Biomarkers
- Cervical Cancer and HPV Research
- Minimally Invasive Surgical Techniques
- Sarcoma Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Immunotherapy and Immune Responses
- Reproductive Biology and Fertility
- Ovarian function and disorders
- Gynecological conditions and treatments
- Estrogen and related hormone effects
- CRISPR and Genetic Engineering
- Genital Health and Disease
- Cardiac, Anesthesia and Surgical Outcomes
- Renal cell carcinoma treatment
- Virus-based gene therapy research
- PARP inhibition in cancer therapy
- Cancer Diagnosis and Treatment
- Animal Virus Infections Studies
- Multiple and Secondary Primary Cancers
- Angiogenesis and VEGF in Cancer
Koç University
2016-2025
Hospital Universitario Nuestra Señora de Candelaria
2025
Amerikan Hastanesi
2015-2024
Gynecologic Oncology Group
2006-2022
Institut de Virologie
2020-2022
Gazi University
2008-2021
VIB-KU Leuven Center for Cancer Biology
2021
University of Birmingham
2020
AstraZeneca (Brazil)
2020
Stryker (United Kingdom)
2020
To evaluate the addition of humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC).This multicenter placebo-controlled double-blind randomized phase trial (ClinicalTrials.gov identifier: NCT03038100) enrolled patients with untreated International Federation Gynecology Obstetrics (FIGO) OC who either had undergone primary cytoreductive surgery macroscopic residual...
The European Society of Gynaecological Oncology, the for Medical Oncology (ESMO) and Pathology held a consensus conference (CC) on ovarian cancer 15-16 June 2022 in Valencia, Spain. CC panel included 44 experts management pathology, an ESMO scientific advisor methodologist. aim was to discuss new or contentious topics develop recommendations improve harmonise patients with cancer. Eighteen questions were identified discussion under four main topics: (i) pathology molecular biology, (ii)...
STUDY QUESTIONDo different chemotherapy drugs exert the same magnitude of cytotoxicity on dormant primordial follicles and growing follicle fraction in ovary vivo mitotic non-luteinized non-mitotic luteinized granulosa cells vitro?
The European Society of Gynaecological Oncology (ESGO) developed and established for the first time in 2016, updated 2020, quality indicators advanced ovarian cancer surgery to audit improve clinical practice Europe beyond. As a sequela continuous effort oncologic care patients with cancer, ESGO issued 2018 consensus guidance jointly Medical addressing multidisciplinary fashion 20 selected key questions management ranging from molecular pathology palliation primary relapse disease. In order...
<h3>Objective</h3> Management of endometrial cancer is advancing, with accurate staging crucial for guiding treatment decisions. Understanding sentinel lymph node (SLN) involvement rates across molecular subgroups essential. To evaluate SLN in early-stage (International Federation Gynecology and Obstetrics 2009 I–II) cancer, considering subtypes new European Society Gynaecological Oncology (ESGO) risk classification. <h3>Methods</h3> The SENECA study retrospectively reviewed data from 2139...
The prognostic significance of isolated tumor cells (≤0.2 mm) in sentinel lymph nodes (SLNs) endometrial cancer patients is still unclear. Our aim was to assess the value with low risk who underwent SLN biopsy and did not receive adjuvant therapy. Outcomes were compared node negative patients.
Is there any in vitro evidence for or against ovarian protection by co-administration of a GnRH agonist with chemotherapy human? The leuprolide acetate cytotoxic agents does not preserve reserve vitro. Randomized controlled trials the gonadotrophin-releasing hormone (GnRH) agonists adjuvant to function have shown contradictory results. This fact, together lack proven molecular mechanism action (GnRHa) places this approach as fertility preservation strategy under scrutiny. We therefore aimed...
Background Optimizing and ensuring the quality of surgical care is essential to improve management outcome patients with cervical cancer. To develop a list indicators for treatment cancer that can be used audit clinical practice. Methods Quality were developed using four-step evaluation process included systematic literature search identify potential indicators, in-person meetings an ad hoc group international experts, internal validation process, external review by large panel European...